Mannkind, Game-Chancer in Sachen Diabetik? (Seite 202)

[questionmark]

50% klingt gut, wir sind aber noch gut unter 2 USD , da muss noch mehr kommen

[Apollonius]

Antwort auf Beitrag Nr.: 58.610.826 von peppino23 am 04.09.18 14:39:59

Siehst du alles wird gut!

Man muss die Zeichen erkennen und Eier in der Hose haben!

[price-of-success]

Freitag nun bitte

600+

[Magnetfeldfredy]

Die basher müssen zugeben dass Mannkind sofort 55 Millionen US Dollar erhält und so Zeit haben um die Afrezza sales zu pushen, außerdem werden double digits bei den Trepto-sales fällig:

Why MannKind Corporation Stock Is Skyrocketing Today
[Motley Fool]
Brian Feroldi, The Motley Fool
,Motley Fool•September 4, 2018
What happened

Shares of MannKind Corporation (NASDAQ: MNKD) are soaring today, up 43% as of 9:35 a.m. EDT, following news that the company has struck up a collaborative partnership with United Therapeutics (NASDAQ: UTHR) that features a much-needed up-front payment.
So what

Here are the must-know details of the agreement:

United Therapeutics and MannKind Corporation have signed an exclusive global licensing and collaboration agreement to develop a dry powder formulation of treprostinil as a hopeful treatment for pulmonary arterial hypertension.
United is assuming responsibility for all development, regulatory, and commercial activities. MannKind's role will be to manufacture clinical supplies and initial commercial supplies of the product. Longer-term, the manufacturing responsibilities will be handled by United Therapeutics.
MannKind will receive an up-front payment of $45 million and the ability to earn up to $50 million more in milestone payments. The company is also entitled to receive low-double-digit royalties on any product sales.
MannKind has also provided United Therapeutics with an option to expand its license to include other drugs that could treat pulmonary hypertension. If United exercises its option, then MannKind could receive up to $40 million in additional milestone payments and low-double-digit royalties on any sales.
The two companies have also signed a research deal that provides MannKind with an additional $10 million up-front payment to explore new products outside of the scope of this agreement.

Businessmen looking over a contract
Businessmen looking over a contract

Image source: Getty Images.

MannKind CEO Michael Castagna was enthusiastic about this deal: "We are pleased with this new opportunity to demonstrate the value of our drug and device combination platform for delivering therapeutic products. We believe this collaboration will have the potential to significantly improve the lives of people living with pulmonary arterial hypertension."

Given the immediate non-dilutive cash infusion and long-term optionality of this deal, it is easy to understand why shares are soaring today.
Now what

In total, this deal will immediately add $55 million to MannKind's bank account, which is great news. That buys the company some much-needed time to continue ramping sales of Afrezza.

However, that additional $55 million might not last too long because the company's net loss in the first six months of 2018 was just over $53 million. In essence, MannKind just bought itself about six months of runway. That's certainly a positive development, but it isn't enough to permanently fix this company's troubled financial situation.

Overall, investors have every right to cheer today's announcement, but success in the medium and long term still hinges on the MannKind's ability to turn Afrezza into a highly profitable commercial product. Since the company is nowhere close to claiming victory on that front, I continue to believe that caution is warranted.

[sir1]

Antwort auf Beitrag Nr.: 58.611.339 von Magnetfeldfredy am 04.09.18 15:22:17

schöne news, jetzt hand mannkind eine neue Chance.
Die wertungsansätze müssen geändert werden, nicht lange und Mannkind liegt bei 5 Dollar.


.....lets dance

[Magnetfeldfredy]

Doch, die shorts werden alles versuchen billig zu covern und es wird dauern bis die Masse den Deal versteht, heute CC in USA!
Dann wird Mike Castagna aufklären!

[price-of-success]

Antwort auf Beitrag Nr.: 58.610.361 von Magnetfeldfredy am 04.09.18 14:00:27

der Markt hat es- so der Eindruck- noch nicht gecheckt.....

[Magnetfeldfredy]

Hier gehts um was ganz anderes, 90 Millionen upfront haben Mannkind vor der Pleite gerettet und das proof of concept für die Technosphere Technologie geliefert, Mannkinds delivery Platform wurde immer belächelt, bis heute, das ist ein Gamechanger für Mannkind!

[price-of-success]

Antwort auf Beitrag Nr.: 58.610.361 von Magnetfeldfredy am 04.09.18 14:00:27

Frage: können die 80? oder so AFREZZA Vertreter jetzt mehr anbieten, als ein phänomenales single product?

[Magnetfeldfredy]

United Therapeutics bezeichnet Mannkinds device: revolutinoary!

United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery

Email
Share
Share
Tweet
Save
Print
Order Reprints

Martine Rothblatt, CEO of United Therapeutics, has struck another big deal to commercialize a new delivery device for a pulmonary arterial hypertension drug.
Enlarge

Martine Rothblatt, CEO of United Therapeutics, has struck another big deal to commercialize a new delivery device for a pulmonary arterial hypertension drug.

Lenzy Ruffin
In This Article

Alfred Mann Person
Health Care Industry
MannKind Corp. Company
Manufacturing Industry
Martine Rothblatt Person
United Therapeutics Company

By Michael Neibauer – Associate Editor, Washington Business Journal
46 minutes ago

Silver Spring-based United Therapeutics Corp. announced Tuesday that it will pay a California company $95 million to partner in the development, manufacture and commercialization of a new treatment for pulmonary arterial hypertension.

Under the deal with MannKind Corp. (NASDAQ: MNKD), United Therapeutics (NASDAQ: UTHR) will be responsible for global development, regulatory and commercial activities for the dry power formulation and inhalation delivery of treprostinil, the active ingredient in United Therapeutics' flagship product Remodulin. The system is currently in the clinical trials stage.

Westlake Village, California-based MannKind will manufacture clinical supplies and initial commercial supplies out of its Danbury, Connecticut plant, while United Therapeutics will manufacture long-term commercial supplies of the product.

The deal provides for a $45 million upfront payment to Mannkind and potential payments of another $50 million, dependent on certain development targets. Mannkind will also be eligible for “low double-digit royalties” on net sales of the product, per a release.

United Therapeutics has a long history with treprostinil and MannKind. Exactly 21 years ago, UT CEO Martine Rothblatt said in a statement, the Maryland company combined one of its creations with a parenteral infusion pump called MiniMed 407c, invented by Alfred Mann, to create Remodulin.

Rothblatt said the new inhalation devices will be "revolutionary."

In late July, United Therapeutics received Federal Drug Administration approval for an implantable pump for Remodulin. The drug, perhaps soon-to-be-available as a generic, generated sales of $286.3 million in the first six months of the year for United Therapeutics.

The deal extends beyond treprostinil. MannKind granted United Therapeutics an option to expand the license to include other active ingredients for the treatment of pulmonary hypertension — subject to an additional $40 million payment per license. And the California company will get another $10 million immediately to conduct research “on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement.”
Trending
Commercial Real Estate
Behind the deal: How Virginia landed the $3B Micron expansion
Micron President and CEO Sanjay Mehrotra at an announcement for his company's $3 billion, 1,100-job expansion in Manassas.
Commercial Real Estate
Micron to invest $3B in Manassas operation, add 1,100 jobs
Pictured here is Micron Technology's facility in Manassas, where the company employs 1,500 workers.
Home of the Day
Gorgeous Eastern Shore Estate
Sponsored Listing